Protocol for a multicentre, double-blind, randomised, placebo-controlled trial of riociguat on peak cardiac index during exercise in patients with chronic thromboembolic pulmonary hypertension after balloon pulmonary angioplasty (THERAPY-HYBRID-BPA trial)

Hiroto Shimokawahara,Takumi Inami,Kayoko Kubota,Yu Taniguchi,Hiroya Hashimoto,Akiko M Saito,Masahiro Sekimizu,Hiromi Matsubara

doi:10.1136/bmjopen-2023-072241

Protocol for a multicentre, double-blind, randomised, placebo-controlled trial of riociguat on peak cardiac index during exercise in patients with chronic thromboembolic pulmonary hypertension after balloon pulmonary angioplasty (THERAPY-HYBRID-BPA trial)

Hiroto Shimokawahara, Takumi Inami + Show 6 more

Open Access

https://doi.org/10.1136/bmjopen-2023-072241

Copy DOI

Journal: BMJ open	Publication Date: Jul 1, 2023
Citations: 1	License type: CC BY-NC 4.0

Affiliation: Okayama Medical Center, Kyorin University Hospital, Kagoshima University, Kobe University, Nagoya City University, Nagoya Medical Center

#Chronic Thromboembolic Pulmonary Hypertension #Peak Cardiac Index + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

ObjectivesBalloon pulmonary angioplasty (BPA) and medical therapy, such as soluble guanylate cyclase stimulators, are recommended treatments for patients with chronic thromboembolic pulmonary hypertension (CTEPH) who are ineligible for pulmonary endarterectomy...

Full Text